Articles from Sunshine Biopharma Inc.

FORT LAUDERDALE, FL / ACCESS Newswire / July 20, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications today announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor, MR1-114, with nanomolar potency in at least three variants of the SARS-CoV-2 virus in vitro. MR1-114 was found to be efficacious in a mouse model of SARS-CoV-2 infection by repeated oral administration. This peer-reviewed study marks an important milestone for Sunshine Biopharma in its effort to develop an effective treatment for SARS Coronavirus infections. A copy of the publication (J. Med. Chem. 2026, 69, 8433−8450) is available on the Company website at www.sunshinebiopharma.com/scientific-publications/.

FORT LAUDERDALE, FL / ACCESS Newswire / June 25, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Anastrozole tablets of 1mg for the Canadian market. Anastrozole is the generic equivalent of the brand name breast cancer drug, Arimidex®.